Evogene (EVGN) Non Operating Interest Expenses (2013 - 2026)

Evogene has disclosed Non Operating Interest Expenses across 14 years of filings, most recently posting -$168000.0 for Q2 2026.

• In Q2 2026, Non Operating Interest Expenses rose 70.47% year-over-year to -$168000.0; the TTM figure through Jun 2026 stood at -$4.9 million (down 16.51% YoY), while the FY2025 annual figure was -$1.8 million, up 45.18% from the prior year.
• Non Operating Interest Expenses came in at -$168000.0 for Q2 2026 at Evogene, up from -$3.9 million in the prior quarter.
• In the past five years, Non Operating Interest Expenses ranged from a high of -$71000.0 in Q4 2023 to a low of -$3.9 million in Q1 2026.
• Average Non Operating Interest Expenses over 5 years is -$772833.3, with a median of -$302500.0 recorded in 2022.
• Year-over-year, Non Operating Interest Expenses soared 88.53% in 2023 and slumped 2550.46% in 2024.
• Over 5 years, Non Operating Interest Expenses stood at -$163000.0 in 2022, then surged by 56.44% to -$71000.0 in 2023, then slumped by 253.52% to -$251000.0 in 2024, then slumped by 39.44% to -$350000.0 in 2025, then soared by 52.0% to -$168000.0 in 2026.
• Per Business Quant data, the three most recent Non Operating Interest Expenses figures were -$168000.0 in Q2 2026, -$3.9 million in Q1 2026, and -$350000.0 in Q4 2025.